#United States #New York #Levi & Korsinsky #Zevra Therapeutics #arimoclomol

Investigation Launched: Zevra Therapeutics Under Scrutiny

In a recent turn of events, investors have witnessed a significant downturn in the stock value of Zevra Therapeutics (NASDAQ: ZVRA), which plummeted nearly 24% in pre-market trading. This dramatic decline occurred following the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) releasing a negative opinion regarding the Marketing Authorization Application for the company's lead product, arimoclomol (branded as Meplyffa). The drug is intended for treating Niemann-Pick disease type C.

The unexpected drop in stock price signals a severe market reaction, marking the most considerable single-day percentage loss that Zevra has encountered in over five years. Financial analysts and investors alike described the event as alarming, prompting significant interest from law firms such as Levi & Korsinsky, which has initiated an investigation to determine if shareholders burdened by losses have grounds for potential securities law claims.

Following the negative ruling from CHMP, Zevra Therapeutics has expressed its intent to challenge the decision and is asking for a re-examination. Meanwhile, the company has emphasized its commitment to continuing to provide arimoclomol to qualifying patients through its global Expanded Access Program while it navigates these challenging regulatory waters.

Investors Encouraged to Report Losses

Levi & Korsinsky is reaching out to investors who have experienced financial loss due to the recent stock drop, urging them to report any relevant information about their investments. Reports indicate that the adverse reaction was instigated by concerns over the approval of arimoclomol, which is pivotal for both the company and the patients it aims to serve.

Who Can Participate in the Investigation?

The investigation targets investors who acquired shares or securities of Zevra Therapeutics and experienced financial losses around the time of the stock's decline. Eligibility for participation can hinge on factors such as the date of the purchase and documented losses rather than current holding status.

FAQs about the Investigation

Here are some frequently asked questions that may provide clarity for concerned investors:

• - How much did the ZVRA stock drop?

The stock saw an approximate 24% decrease following the announcement from CHMP on July 24, 2026.

• - Are misleading statements part of the investigation?

Yes, the inquiry is focused on whether Zevra Therapeutics made statements regarding arimoclomol and its regulatory outlook that could be deemed misleading before the July 24 ruling.

• - What documentation is necessary to participate?

Interested investors should provide brokerage statements or trade confirmations that reflect their purchase history, share quantities, prices, and any sales data.

• - What if I no longer hold ZVRA shares?

Individuals can still participate in the investigation if they sold their shares at a loss, as eligibility is not contingent on current holdings.

• - Are there costs to participate?

No upfront costs are associated with participation in the investigation, as it operates largely on a contingency basis.

Conclusion

With the investigation being actively pursued by legal experts, affected investors are advised to stay informed and take appropriate action. This moment presents a critical juncture for both Zevra Therapeutics and its stakeholders as the firm navigates the complexities arising from this regulatory setback. Potential claimants are encouraged to document their experience and losses, ensuring they are prepared as the circumstances continue to unfold.

For those interested in learning more or who wish to report their ZVRA losses, they can do so by contacting Levi & Korsinsky at the number provided.